TY - JOUR
T1 - Metabolic Engineering for Glycyrrhetinic Acid Production in Saccharomyces cerevisiae
AU - Guan, Ruobing
AU - Wang, Mengge
AU - Guan, Zhonghua
AU - Jin, Cheng Yun
AU - Lin, Wei
AU - Ji, Xiao Jun
AU - Wei, Yongjun
N1 - Publisher Copyright:
© Copyright © 2020 Guan, Wang, Guan, Jin, Lin, Ji and Wei.
PY - 2020/11/19
Y1 - 2020/11/19
N2 - Glycyrrhetinic acid (GA) is one of the main bioactive components of licorice, and it is widely used in traditional Chinese medicine due to its hepatoprotective, immunomodulatory, anti-inflammatory and anti-viral functions. Currently, GA is mainly extracted from the roots of cultivated licorice. However, licorice only contains low amounts of GA, and the amount of licorice that can be planted is limited. GA supplies are therefore limited and cannot meet the demands of growing markets. GA has a complex chemical structure, and its chemical synthesis is difficult, therefore, new strategies to produce large amounts of GA are needed. The development of metabolic engineering and emerging synthetic biology provide the opportunity to produce GA using microbial cell factories. In this review, current advances in the metabolic engineering of Saccharomyces cerevisiae for GA biosynthesis and various metabolic engineering strategies that can improve GA production are summarized. Furthermore, the advances and challenges of yeast GA production are also discussed. In summary, GA biosynthesis using metabolically engineered S. cerevisiae serves as one possible strategy for sustainable GA supply and reasonable use of traditional Chinese medical plants.
AB - Glycyrrhetinic acid (GA) is one of the main bioactive components of licorice, and it is widely used in traditional Chinese medicine due to its hepatoprotective, immunomodulatory, anti-inflammatory and anti-viral functions. Currently, GA is mainly extracted from the roots of cultivated licorice. However, licorice only contains low amounts of GA, and the amount of licorice that can be planted is limited. GA supplies are therefore limited and cannot meet the demands of growing markets. GA has a complex chemical structure, and its chemical synthesis is difficult, therefore, new strategies to produce large amounts of GA are needed. The development of metabolic engineering and emerging synthetic biology provide the opportunity to produce GA using microbial cell factories. In this review, current advances in the metabolic engineering of Saccharomyces cerevisiae for GA biosynthesis and various metabolic engineering strategies that can improve GA production are summarized. Furthermore, the advances and challenges of yeast GA production are also discussed. In summary, GA biosynthesis using metabolically engineered S. cerevisiae serves as one possible strategy for sustainable GA supply and reasonable use of traditional Chinese medical plants.
KW - Saccharomyces cerevisiae
KW - glycyrrhetinic acid
KW - metabolic engineering
KW - microbial cell factories
KW - natural product production
UR - http://www.scopus.com/inward/record.url?scp=85097216857&partnerID=8YFLogxK
U2 - 10.3389/fbioe.2020.588255
DO - 10.3389/fbioe.2020.588255
M3 - 文献综述
AN - SCOPUS:85097216857
SN - 2296-4185
VL - 8
JO - Frontiers in Bioengineering and Biotechnology
JF - Frontiers in Bioengineering and Biotechnology
M1 - 588255
ER -